Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 5Lung Neoplasms 3Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1

Interventions

Carboplatin 67Cisplatin 57Paclitaxel 42Radiotherapy 35Pemetrexed 34Gemcitabine 31Docetaxel 31Etoposide 25pembrolizumab 21Vinorelbine 20Erlotinib Hydrochloride 13Magnetic Resonance Spectroscopy 12Gefitinib 11Specimen Handling 10Radiosurgery 10Drug Therapy 10Bevacizumab 10durvalumab 9Nivolumab 9Vinblastine 6Topotecan 6Surgical Procedures, Operative 6Cyclophosphamide 6atezolizumab 5Standard of Care 5Platinum 5Immunoglobulin G 5Ifosfamide 5Disulfides 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Lung Neoplasms × amrubicin × Clear all
NCT02481830 2023-07-27

CheckMate331

Bristol-Myers Squibb

Phase 3 Completed
569 enrolled 13 charts
Thoracic

Lung Neoplasms

NCT00547651 2019-11-06

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Celgene

Phase 3 Completed
637 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00660504 2014-07-18

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Sumitomo Pharma (Suzhou) Co., Ltd.

Phase 3 Completed
300 enrolled 10 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡